SCHEMBL4907688

SCHEMBL4907688

CCc1cncc(-c2nc(C)nc3sc(C(N)=S)c(N)c23)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BRAF P15056 3/20 0.41
PDE4A P27815 1/20 0.40
PDE4B Q07343 1/20 0.40
PDE4C Q08493 1/20 0.40
PDE4D Q08499 1/20 0.40
IKBKB O14920 8/20 0.39
KDM4E B2RXH2 6/20 0.38
ALDH1A1 P00352 4/20 0.38
GAA P10253 3/20 0.38
MAPT P10636 3/20 0.38
GLA P06280 2/20 0.38
ATM Q13315 2/20 0.38
HPGD P15428 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
CASP1 P29466 1/20 0.38
CASP7 P55210 1/20 0.38
HSD17B10 Q99714 1/20 0.38
CHUK O15111 1/20 0.37
PRKACA P17612 1/20 0.37
PRKACG P22612 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4909271 0.84 BRAF (0.47) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4907129 0.83 BRAF (0.56) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4900838 0.80 BRAF (0.43) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4907672 0.76 BRAF (0.49) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4909708 0.75 BRAF (0.52) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4904202 0.74 BRAF (0.61) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4903949 0.73 BRAF (0.51) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4908199 0.72 BRAF (0.70) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4908318 0.72 BRAF (0.57) BRAFPDE4APDE4BPDE4CPDE4D
SCHEMBL4907258 0.72 BRAF (0.41) BRAFPDE4APDE4BPDE4CPDE4D

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith MCKENNA JEFFREY M 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080004271-A1 Inhibitors of TNFalpha, PDE4 and B-RAF, compositions thereof and methods of use therewith PDE4A, PDE4B, BRAF BRAF 3/4885PDE4A 1/4885PDE4B 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.